Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Masahiro Kashiwaba"'
Autor:
Masato Takahashi, Yuichiro Kikawa, Kosuke Kashiwabara, Naruto Taira, Tsuguo Iwatani, Kojiro Shimozuma, Shoichiro Ohtani, Tetsuhiro Yoshinami, Junichiro Watanabe, Masahiro Kashiwaba, Ken-ichi Watanabe, Masahiro Kitada, Koichi Sakaguchi, Yuko Tanabe, Tomohiko Aihara, Hirofumi Mukai
Publikováno v:
EClinicalMedicine, Vol 74, Iss , Pp 102715- (2024)
Summary: Background: Eribulin prolongs overall survival (OS) of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), particularly in later chemotherapy (ChT) treatment. However, the health-related qua
Externí odkaz:
https://doaj.org/article/1723e209a4034dd0b0e8a27d67cd3241
Autor:
Masataka Sawaki, Naruto Taira, Yukari Uemura, Tsuyoshi Saito, Shinichi Baba, Kokoro Kobayashi, Hiroaki Kawashima, Michiko Tsuneizumi, Noriko Sagawa, Hiroko Bando, Masato Takahashi, Miki Yamaguchi, Tsutomu Takashima, Takahiro Nakayama, Masahiro Kashiwaba, Toshiro Mizuno, Yutaka Yamamoto, Hiroji Iwata, Tatsuya Toyama, Koichiro Tsugawa, Takuya Kawahara, Hirofumi Mukai
Publikováno v:
Breast, Vol 66, Iss , Pp 245-254 (2022)
Purpose: To gauge the effects of treatment practices on prognosis for older patients with HER2-positive early breast cancer, particularly to determine whether adjuvant trastuzumab alone can offer benefit over no adjuvant therapy. This is a prospectiv
Externí odkaz:
https://doaj.org/article/a945b7265854493eb752770a4643139b
Autor:
Yuichiro Kikawa, Kosuke Kashiwabara, Naruto Taira, Tsuguo Iwatani, Kojiro Shimozuma, Shoichiro Ohtani, Tetsuhiro Yoshinami, Junichiro Watanabe, Masahiro Kashiwaba, Ken-ichi Watanabe, Masahiro Kitada, Koichi Sakaguchi, Yuko Tanabe, Tomohiko Aihara, Hirofumi Mukai, Masato Takahashi
Publikováno v:
Cancer Research. 83:P1-03
Background Eribulin is a chemotherapeutic drug that prolongs overall survival (OS) in patients with HER2-negative metastatic breast cancer (MBC), mainly in third-line or later chemotherapy (ChT) [1]. However, health-related quality of life (HRQOL) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcd775153496670f940a41b04553b54c
https://doi.org/10.1158/1538-7445.sabcs22-p1-03-01
https://doi.org/10.1158/1538-7445.sabcs22-p1-03-01
Autor:
Hiroji Iwata, Yutaka Yamamoto, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Shoichiro Ohtani, Masahiro Kashiwaba, Naruto Taira, Tatsuya Toyama, Tomomi Fujisawa, Norikazu Masuda, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi
Publikováno v:
Breast Cancer Research and Treatment. 199:231-241
Purpose Neoadjuvant endocrine therapy (NET) is a treatment option for estrogen receptor-positive (ER+) postmenopausal early breast cancer (EBC). This phase III trial evaluated the prognosis of EBC patients treated with/without chemotherapy (CT) follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6dd2d7e5d5b1688727b86271bb3b50bc
https://doi.org/10.1007/s10549-023-06874-7
https://doi.org/10.1007/s10549-023-06874-7
Autor:
Hiroji Iwata, Tatsuya Toyama, Naruto Taira, Norikazu Masuda, Yutaka Yamamoto, Tomomi Fujisawa, Shoichiro Ohtani, Masahiro Kashiwaba, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi
Publikováno v:
Cancer Research. 82:PD13-09
Background: NET is one of option in postmenopausal PBC with ER+ and molecular signature is useful tool to determine with/without CT after surgery. We presented a relationship between molecular signature and response of NET in this study cohort (BCRT;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::464021cb4c5724422106fff38200d3a4
https://doi.org/10.1158/1538-7445.sabcs21-pd13-09
https://doi.org/10.1158/1538-7445.sabcs21-pd13-09
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 3, Iss 1, Pp 1-8 (2017)
Abstract Background In an evaluation of chemotherapy-induced peripheral neuropathy (CIPN), objectivity may be poor because the evaluation is determined by the patient’s subjective assessment. In such cases, management of neuropathy may be delayed a
Externí odkaz:
https://doaj.org/article/859a16f13a35452996fe829e9cb0dda2
Autor:
Daiki Ikarashi, Kazuyuki Ishida, Masahiro Kashiwaba, Yoichiro Kato, Ei Shiomi, Misato Takayama, Hideaki Komatsu, Ryo Takata, So Ohmori, Tamotsu Sugai, Wataru Obara
Publikováno v:
Urology Case Reports, Vol 16, Iss C, Pp 126-128 (2018)
Externí odkaz:
https://doaj.org/article/98ced7adc9804033aaef033e3ec7b8b1
Autor:
Masahiro Kashiwaba, Takafumi Sangai, Hiroyuki Yasojima, Shinji Ohno, Yutaka Yamamoto, Takashi Morimoto, Norikazu Masuda, Takahiro Nakayama
Publikováno v:
Cancer Research. 81:PS9-52
Background: Nab-paclitaxel(nab-PTX) is improved taxane in terms of solubility, alcohol-free and reduced incidence of anaphylaxis. On the other hand, chemotherapy-induced peripheral neuropathy (PN) is known as a major adverse event which was failed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9149dddea102fc8122b7a8a0231aaead
https://doi.org/10.1158/1538-7445.sabcs20-ps9-52
https://doi.org/10.1158/1538-7445.sabcs20-ps9-52
Autor:
Taira Naruto, Satoshi Morita, Koichiro Tsugawa, Masato Takahashi, Hiroji Iwata, Yoshie Hasegawa, Masakazu Toi, Tetsuhiro Yoshinami, Shigehira Saji, Norikazu Masuda, Hiroshi Tada, Kenji Tamura, Takashi Yamanaka, Takayuki Ueno, Fumikata Hara, Shinji Ohno, Yutaka Yamamoto, Toshimi Takano, Tatsuya Toyama, Masahiro Kashiwaba
Publikováno v:
Cancer Research. 81:PD3-11
Background: Patients (pts) with HER2-positive locallyadvanced/metastatic breast cancer (LA/MBC) previously treated with pertuzumab(P)-containing regimens have few therapeutic options. The efficacy of Pre-treatment combined with trastuzumab (T)+chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a87a0c00264a25621f2ab9db4c94d5f
https://doi.org/10.1158/1538-7445.sabcs20-pd3-11
https://doi.org/10.1158/1538-7445.sabcs20-pd3-11
Autor:
Hiroji Iwata, Naruto Taira, Yutaka Yamamoto, Kokoro Kobayashi, Takahiro Nakayama, Tsuyoshi Saito, Masato Takahashi, Michiko Tsuneizumi, Hiroaki Kawashima, Koichiro Tsugawa, Toshiro Mizuno, Shinichi Baba, Tsutomu Takashima, Masahiro Kashiwaba, Miki Yamaguchi, Tatsuya Toyama, Noriko Sagawa, Masataka Sawaki, Yasuo Ohashi, Yukari Uemura, Hirofumi Mukai, Hiroko Bando
Publikováno v:
Cancer Research. 80:P3-14
Background: The randomized controlled trial (RCT) is accepted as the standard clinical trial to decide a standard therapy, but it remains unclear whether or not elderly patients benefit as much as other patients from participation in an RCT. In the R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42ebe1aa2ee97c37a977791b453a9ae6
https://doi.org/10.1158/1538-7445.sabcs19-p3-14-02
https://doi.org/10.1158/1538-7445.sabcs19-p3-14-02